The boom of copyright’s drug initially drove significant expansion in the pharmaceutical sector, producing a perception of easy gains. However, funding in companies solely reliant on top-selling drugs like Viagra presents considerable risks. Exclusive rights expiry has resulted in off-brand rivalry, decreasing revenue segment and potentially decr

The recent surge in funding into boutique pharmaceutical companies, particularly those focusing on experimental therapies and difficult drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the promise for game-changing treatments and significant returns is certain, the connected risks are also significant. Ma